Atezolizumab-Enhanced Chemotherapy Halves Recurrence in Stage III dMMR Colon Cancer

Data from 712 patients show that integrating immunotherapy with chemotherapy could establish a precision oncology approach for stage III colon cancers with mismatch repair defects.